Please login to the form below
Keytruda
This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma. ... The results presented demonstrated that the combination of Lenvima plus Keytruda
Latest news
-
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
Elsewhere in its Q2 results, Merck saw sales growth for its blockbuster immunotherapy Keytruda, which grew by 23% to $4.2bn, reflecting continued demand in the major non-small cell lung
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process. ... The Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process for the treatment of certain endometrial cancer patients.
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... Now, Merck has additional data to make its case for
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data. ... Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%.
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Instead of targeting a specific genetic defect, Keytruda targets tumours that have a high degree of genetic instability. ... As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda
More from news
Approximately 169 fully matching, plus 278 partially matching documents found.
Latest Intelligence
-
Putting commercial intelligence at the heart of strategy
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
-
20 for 2020 – Five pharma companies to watch
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
-
25 Women Leaders in UK Healthcare
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
-
Immuno-oncology in 2019: the rapid evolution continues
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
-
BMS appoints new commercial leader, Davies joins Eisai and more
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
-
18 SWITCHED ONcology: The Big Communication
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
-
A stumble, but not a fall – what’s next for Opdivo?
Impressively, Opdivo consistently outperformed Merck &Co.'s ($MRK) Keytruda (pembrolizumab), racking up $1.58 billion in sales during the first half of 2016 compared to $563 million earned by its main ... Rubbing salt into BMS’s wounds, Merck's
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- PM announces plans to lift England’s COVID-19 restrictions
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Developing Innovative Digital Strategies to Engage Patients
- GSK appoint Tony Wood as chief scientific officer
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Cervical Cancer Prevention Month
- Why pharma must get smart in its approach to customer engagement
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- AstraZeneca's Enhertu receives FDA grant for priority review
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
PMHub
VISFO
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
- Hybrid working: Insights and tips for success
- Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
